nucala mepolizumab 100 mg powder for injection
glaxosmithkline australia pty ltd - mepolizumab, quantity: 100 mg - injection, powder for - excipient ingredients: polysorbate 80; water for injections; dibasic sodium phosphate heptahydrate; sucrose - severe eosinophilic asthma,nucala is indicated as an add-on treatment for severe eosinophilic asthma in patients aged 12 years and over (see section 5.1 pharmacodynamic properties, clinical trials).,chronic rhinosinusitis with nasal polyps (crswnp),nucala is indicated as add-on treatment in adult patients (18 years and above) with severe chronic rhinosinusitis with nasal polyps (crswnp) with an inadequate response to intranasal corticosteroids (see section 5.1 pharmacodynamic properties, clinical 2 trials).,relapsed or refractory egpa,nucala is indicated as an add-on treatment for relapsing or refractory eosinophilic granulomatosis with polyangiitis (egpa) in adult patients aged 18 years and over (see section 5.1 pharmacodynamic properties, clinical trials).
dupixent
sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agents for dermatitis, excluding corticosteroids - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy.asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5.1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment.children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment.chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy.eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.
nucala mepolizumab 100 mg solution for injection in pre-filled pen
glaxosmithkline australia pty ltd - mepolizumab, quantity: 100 mg - injection, solution - excipient ingredients: sucrose; dibasic sodium phosphate heptahydrate; citric acid monohydrate; polysorbate 80; disodium edetate; water for injections - severe eosinophilic asthma,nucala is indicated as an add-on treatment for severe eosinophilic asthma in patients aged 12 years and over (see section 5.1 pharmacodynamic properties, clinical trials).,chronic rhinosinusitis with nasal polyps (crswnp),nucala is indicated as add-on treatment in adult patients (18 years and above) with severe chronic rhinosinusitis with nasal polyps (crswnp) with an inadequate response to intranasal corticosteroids (see section 5.1 pharmacodynamic properties, clinical 2 trials).,relapsed or refractory egpa,nucala is indicated as an add-on treatment for relapsing or refractory eosinophilic granulomatosis with polyangiitis (egpa) in adult patients aged 18 years and over (see section 5.1 pharmacodynamic properties, clinical trials).
nucala mepolizumab 100 mg solution for injection in pre-filled syringe
glaxosmithkline australia pty ltd - mepolizumab, quantity: 100 mg - injection, solution - excipient ingredients: sucrose; dibasic sodium phosphate heptahydrate; citric acid monohydrate; polysorbate 80; disodium edetate; water for injections - severe eosinophilic asthma,nucala is indicated as an add-on treatment for severe eosinophilic asthma in patients aged 12 years and over (see section 5.1 pharmacodynamic properties, clinical trials).,chronic rhinosinusitis with nasal polyps (crswnp),nucala is indicated as add-on treatment in adult patients (18 years and above) with severe chronic rhinosinusitis with nasal polyps (crswnp) with an inadequate response to intranasal corticosteroids (see section 5.1 pharmacodynamic properties, clinical 2 trials).,relapsed or refractory egpa,nucala is indicated as an add-on treatment for relapsing or refractory eosinophilic granulomatosis with polyangiitis (egpa) in adult patients aged 18 years and over (see section 5.1 pharmacodynamic properties, clinical trials).
kaparlon-s
anfarm hellas s.a. 4 achaias str. & trizinias 14564 kifissia, attiki, greece - enalapril maleate - tablet - enalapril maleate 5 mg - agents acting on the renin-angiotensin system
kaparlon-s
anfarm hellas s.a. 4 achaias str. & trizinias 14564 kifissia, attiki, greece - enalapril maleate - tablet - enalapril maleate 20 mg - agents acting on the renin-angiotensin system
daptomycin melita pharm 350mg powder for solution for injection or infusion
melita pharm, s.l. c/roma, 6-10, 08023 - barcelona,, spain - daptomycin - powder for solution for injection/infusion - daptomycin 350 mg - antibacterials for systemic use
daptomycin melita pharm 500mg powder for solution for injection or infusion
melita pharm, s.l. c/roma, 6-10, 08023 - barcelona,, spain - daptomycin - powder for solution for injection/infusion - daptomycin 500 mg - antibacterials for systemic use
zepraxen 350mg powder for solution for injection/infusion
vocate pharmaceuticals s.a 150, gounari str, 166 74 glyfada, athens, greece - daptomycin - powder for solution for injection/infusion - daptomycin 350 mg - antibacterials for systemic use
zepraxen 500mg powder for solution for injection/infusion
vocate pharmaceuticals s.a 150, gounari str, 166 74 glyfada, athens, greece - daptomycin - powder for solution for injection/infusion - daptomycin 500 mg - antibacterials for systemic use